Kintara Therapeutics Inc (KTRA) has released an update.
Kintara Therapeutics, a biopharmaceutical developer of solid tumor cancer therapies, has reported a decreased net loss in Q3 of fiscal 2024, with a current net loss of $2.0 million, down from $3.3 million in the previous year. The company also announced a merger with immune-oncology firm TuHURA Biosciences, signaling growth and the advancement of a promising photodynamic therapy study for metastatic breast cancer, supported by a NIH grant.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
